Summary
Oral administration of mixture of extractive glycosaminoglycans to a group of renal stone formers led to a significant decrease in oxalate self-exchange and in erythrocytes membrane protein phosphorylation traits that are abnormal in the majority of patients with idiopathic calcium nephrolithiasis. The action of glycosaminoglycans at the cellular level is probably due to their modulating activity on certain membrane protein kinases.
The proven effect of the glycosaminoglycans opens a new pharmacological approach to the prevention of recurrent nephrolithiasis.
Article PDF
Similar content being viewed by others
References
Baggio B, Gambaro G, Marchini F, Cicerello E, Borsatti A (1984) Raised transmembrane oxalate flux in red blood cells in idiopathic calcium oxalate nephrolithiasis. Lancet II: 12–14
Baggio B, Gambaro G, Marchini F, Cicerello E, Tenconi R, Clementi M, Borsatti A (1986) An inheritable anomaly of red-cell oxalate transport in “primary” calcium nephrolithiasis correctable with diuretics. N Engl J Med 314: 599–604
Baggio B, Clari G, Marzaro G, Gambaro G, Borsatti A, Moret V (1986) Altered red blood cell membrane protein phosphorylation in idiopathic calcium oxalate nephrolithiasis. IRCS Med Sci 14: 368–369
Baggio B, Clari G, Marzaro G, Gambaro G, Borsatti A, Moret V (1987) Erythrocyte membrane protein phosphorylation in urolithiasis. Contr Nephrol 58: 156–159
Robertson WG, Peacock M, Nordin BEC (1973) Inhibitors of the growth and aggregation of calcium oxalate crystals in vitro. Clin Chim Acta 43: 31–37
Bowyer RG, Brockis JG, McCulloch RK (1979) Glycosaminoglycans as inhibitors of calcium oxalate crystal growth and aggregation. Clin Chim Acta 95: 23–28
Ryall RL, Harnett RM, Marshall VR (1981) The effect of urine, pyrophosphate, citrate, magnesium and glycosaminoglycans on the growth and aggregation of calcium oxalate crystals in vitro. Clin Chim Acta 112: 349–356
Gjaldbaek JC (1982) Inhibition of chondroitin sulphate and heparin on the growth and agglomeration of calcium oxalate monohydrate crystals in vitro. Clin Chim Acta 120: 363–365
Kok DJ, Papapoulos SE, Blomen LJMJ, Bijvoet OLM (1988) Modulation of calcium oxalate monohydrate crystallization kinetics in vitro. Kidney Int 34: 346–350
Robertson WG, Peacock M, Heyburn PJ, Marshall DH, Clark PB (1978) Risk factors in calcium stone disease of the urinary tract. Br J Urol 50: 449–454
Baggio B, Gambaro G, Oliva O, Favaro S, Borsatti A (1982) Calcium oxalate nephrolithiasis: an easy way to detect an imbalance between promoting and inhibiting factors. Clin Chim Acta 124: 149–155
Baggio B, Gambaro G, Cicerello E, Mastrosimone S, Marzaro G, Borsatti A, Pagano F (1987) Urinary excretion of glycosaminoglycans in urological disease. Clin Biochem 20: 449–450
Martelli A, Marchesini B, Buli P, Lambertini F, Rusconi R (1985) Urinary excretion of main glycosaminoglycans in stone formers and controls. In: Schwille PO, Smith LH, Robertson WG, Vahlensieck W (eds) Urolithiasis and related clinical research. Plenum Press, New York, pp 333–358
Baggio B, Marzaro G, Gambaro G, Marchini F, Cicerello E, Matrosimone S, Williams HE, Borsatti A (1989) Decreased erythrocyte glycosaminoglycans content in idiopathic calcium-oxalate nephrolithiasis. In: Walker VR, Sutton RAL, Cameron BEC, Pak CYC, Robertson WG (eds) Urolithiasis. Plenum Press, New York 247
Baggio B, Clari G, Gambaro G, Marchini F, Marchi E, Mastacchi R, Marzaro G (1987) Effects of glycosaminoglycans on some cellular abnormalities associated with idiopathic calcium-oxalate nephrolithiasis. In: Martelli A, Buli PF, Marchesini B (eds) Inhibitors of crystallization in renal lithiasis and their clinical application. Acta Medica, Roma 211–213
Hathaway GM, Lubben TH, Thraugh JA (1980) Inhibition of casein kinase II by heparin. J Biol Chem 255: 8038–8041
Lecomte MC, Boivin P (1981) Different sensitivity of human red cell casein kinases towards glycosaminoglycans. Biochem Biophys Res Commun 102: 420–425
Clari G, Ferrari S (1983) Kinetic behaviour of human erythrocyte casein kinases. Effect of 2,3-bisphosphoglycerate and heparin. Ital J Biochem 42: 174–188
Boivin P, Galand C, Bertrand O (1985) Interactions of the human red cell membrane tyrosine kinase with heparin. FEBS Lett 186: 89–92
Radhakrishnamurthy B, Chakravarthi S, Bhandaru R, Berendson G, Stanzani L, Mastacchi R (1986) Studies of chemical and biologic properties of a fraction of sulodexide, a heparin-like glycosaminoglycan. Atherosclerosis 60: 141–149
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193: 265–275
Gambaro G, Marchini F, Bevilacqua M, Borsatti A, Baggio B (1989) Erythrocyte abnormality in oxalate self-exchange and urinary acidification in idiopathic calcium-oxalate stone formers. In: Walker R, Sutton RAL, Cameron BEC, Pak CYC, Robertson WG (eds) Urolithiasis. Plenum Press, New York 451–452
Morton AK, Haydn P, Edwards E, Allen JC, Phillips GO (1981) An evaluation of the oral administration of commercial and fractionated heparin samples in rats. Int J Pharm 9: 321–335
Larsen AK, Lund DP, Langer R, Folkman J (1986) Oral heparin results in the appearance of heparin fragments in the plasma of rats. Proc Natl Acad Sci 83: 2964–2968
Folkman J, Langer R, Linhardt RJ, Handenschild C, Taylor S (1983) Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 221: 719–725
Norman RW, Scurr DS, Robertson WG, Peacock M (1985) Sodium pentosan polysulphate as a polyanionic inhibitor of calcium oxalate cristallization in vitro and in vivo. Clin Sci 68: 369–371
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Baggio, B., Gambaro, G., Marzaro, G. et al. Effects of the oral administration of glycosaminoglycans on cellular abnormalities associated with idiopathic calcium oxalate nephrolithiasis. Eur J Clin Pharmacol 40, 237–240 (1991). https://doi.org/10.1007/BF00315202
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315202